Key result
Rivaroxaban was associated with a similar six-month risk of recurrent VTE (3.03% vs 3.13%; absolute risk difference -0.11%, 95% CI -0.76 to 0.54) compared with VKAs in patients with VTE.
Why the study?
Does rivaroxaban reduce recurrent VTE and bleeding compared to VKAs in patients with venous thromboembolism?
Population
12,318 patients diagnosed with venous thromboembolism between 2013 and 2015 from Danish nationwide registries.
Comparison
Rivaroxaban vs Vitamin K antagonists (VKAs)
Design
Cohort
Follow-up
six months
Authors
Loading...
Supports similar VTE recurrence risk with rivaroxaban versus VKAs in routine care; leaves open need for randomized confirmation.
Cohort (n=12,318)
Yes
Does rivaroxaban reduce recurrent VTE and bleeding compared to VKAs in patients with venous thromboembolism?
Absolute Risk Reduction: -0.11 (95% CI -0.76–0.54)
Absolute Event Rate: 3.03% vs 3.13%
Absolute Risk Reduction: -0.11%
In a nationwide Danish cohort, rivaroxaban demonstrated comparable effectiveness and safety to VKAs for the treatment of VTE in routine clinical practice.
Sindet‐Pedersen et al. (2017) conducted a cohort in venous thromboembolism (VTE) (n=12,318). Rivaroxaban vs. Vitamin K antagonists (VKAs) was evaluated on recurrent VTE (absolute risk difference -0.11%, 95% CI -0.76 to 0.54). Rivaroxaban was associated with a similar six-month risk of recurrent VTE (3.03% vs 3.13%; absolute risk difference -0.11%, 95% CI -0.76 to 0.54) compared with VKAs in patients with VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: